Background: The results of phase II clinical trials are usually based on response of tumours to new oncolytic agents as evidenced by radiological imaging techniques. In this trial, all claimed responders were reviewed at a specially convened meeting by the peer group of study investigators and a radiologist, independent of the study institutions.
Introduction
Ovarian cancer is a major cause of death among women with gynaecological malignancies in North-eastern Europe and North America. Almost 90% of ovarian malignancies are of the common epithelial type [1] . Platinum-containing regimens as first-line therapy in advanced ovarian cancer have a high response rate of 60% to 80%, but the majority of patients relapse and ultimately succumb to their disease. Recently, taxanes have been identified as having activity in ovarian cancer [2] [3] [4] . Hence they have become established as secondline agents and are increasingly being used as first-line therapy [2] . However, further new agents are required if the outlook is to be improved.
Topotecan (Hycamtin®) is a water soluble semisynthetic analogue of the alkaloid camptothecin which acts via specific inhibition of topoisomerase-1, resulting in damage during DNA replication which leads to cell death [5] . Many studies to date evaluating new anticancer agents have been non-comparative studies relying on historical controls to compare response with existing therapies. Some of these earlier studies did not clearly define the patient population studied, for example the response to prior therapy in the second-line setting, nor were responses independently verified [6] [7] [8] [9] [10] [11] , making such comparisons potentially less reliable. To minimise such problems, increasing use is being made of external review boards, often containing an independent radiologist. Such boards assess all patients with a claimed response and only those patients whose response is confirmed contribute to the response rate reported. This objective assessment of response is of particular value when comparing the effects of different treatments, and has been employed for new agents now reported to show efficacy in a range of solid tumours [12] [13] [14] [15] [16] . Details of the review procedures, however, are rarely provided, so some uncertainty remains as to whether the methods employed are sufficiently consistent for a truly objective comparison to be made. A review of the literature has revealed only a few reports regarding the proportion of claimed responses which were rejected during the review process [17, 18] .
The topotecan programme, including the trial now described, incorporated an independent review for all claimed responses, designed so that predetermined response criteria (modified WHO) could be consistently applied to all patients in the study. Since this review played a key role in the assessment of efficacy, the conduct and results of the procedure are now presented in detail. In addition, the process highlighted a number of general issues concerning the methods used in clinical trials to determine tumour response, and suggestions for how these might be optimised to provide a consistent and objective procedure are also discussed.
Patients and methods
The clinical study of topotecan during which this independent review process took place was carried out in female patients aged at least 18 years who had a diagnosis of FIGO stage III or IV epithelial ovarian cancer Patients had measurable disease, as defined below, and were entered into the study provided they had previously failed first-line therapy with one platinum containing chemotherapeutic regimen. The patient population contained those who were refractory to previous therapy, those who had relapsed within three months of the end of previous therapy as well as those who had relapsed after a disease-free interval of at least three months.
At screening, lesions were categorised into measurable disease, evaluable disease and non-measurable/non-evaluable disease. Measurable disease was defined as bidimensionally measurable lesions with margins clearly defined by diagnostic imaging studies (CTscan, ultrasound or chest radiograph) which had at least one diameter of ^ 2 cm. At least one indicator lesion meeting the criteria for measurable disease was identified for each patient at the time of entry into the study.
Patients followed a treatment regimen of topotecan 1 5 mg/m 2 /day given as an intravenous infusion on five consecutive days, with the treatment repeated every 21 days. The topotecan dose could be increased or decreased, in increments of 0.25 mg/m 2 /day, in the range 1.0-2.0 mg/m 2 /day and/or delayed depending on toxicity assessed by NCI criteria. Lesion assessment took place before the start of each course for those lesions assessed by ultrasound and X-ray, and before every alternate course for those lesions assessed by CT scan. Lesions which were not evaluated at the end of a course, were recorded as such. The overall disease status was also recorded at each assessment based on the WHO criteria as follows.
Complete response: complete disappearance of all known measurable and evaluable disease determined by measurements not less than four weeks apart.
Partial response, a greater than 50% decrease in the sum of products of the greatest length and perpendicular width of all measurable lesions for at least four weeks, with no simultaneous increase in a known lesion ( > 25%) or appearance of new lesions or increase in evaluable disease during this period.
Stable disease: a response between partial response and progression which lasts for eight weeks.
Progression a greater than 25% increase in a single measurable lesion, reappearance of measurable disease; clear worsening of evaluable disease; appearance of any new lesions (including brain metastases even if there was a response outside the brain); significant worsening of a condition presumed to be related to the malignancy.
Partial or complete response could be documented following measurements taken at least four weeks apart; stable disease could be assigned after eight weeks and progression could be assigned provided one full course of topotecan had been received. Lesions were required to be measured bidimensionally rather than measuring the volume because the third dimension cannot be considered reliable due to differences in respiratory excursion during conventional CT scanning. However, when spiral CT, where the examination can be performed in one breath hold, and MRI, where multiplanar images can be acquired, become widely available, then accurate tumour volume measurements will be possible.
Independent review process
The objective of the review process was to determine independently the number of responses to topotecan during the clinical trial. Each set of scans for patients with a claimed response was quantitatively assessed by an independent reviewer and consistently remeasured, before confirming or reclassifying the response record, as appropriate, on the study database.
The principal investigator or a co-investigator at the centres where patients had a documented confirmed partial or complete response attended an independent audit of the claimed responses. For each claimed responder the investigator presented the case. This was then reviewed by the peer group in conjunction with an independent radiologist (S.J.G.). The lesions were examined and remeasured, and peer group discussions led to a final response classification. The study database was updated in accordance with the outcome of the review.
There was one additional patient who did not undergo review at the time, but was assessed by the same independent radiologist using the same criteria at a later date.
Results
In total, 111 patients were enrolled into the study from nine countries. The mean age was 57.3 years and sensitivity to prior chemotherapy was as follows: refractory, 42 patients (37.8%); resistant, 31 patients (27.4%); sensitive, 38 patients (34.2%). Following review, final classification resulted in responses being confirmed for two refractory patients (2.2%), five resistant patients (5.4%) and seven sensitive patients (7.6%) regarding their previous chemotherapy.
At the independent review, 2 complete responses and 22 partial responses (PR; 23.7%), were claimed for 24 patients from 11 centres in 6 of the participating countries. Eighteen patients were assessed by CT scan, four by ultrasound and two by both imaging modalities. No responses were claimed on the basis of chest radiographs. In this study, ultrasound scans were performed before each course of treatment and CT scans were performed after alternate courses. In retrospect, it would have been more consistent to use the same time interval between assessing lesions, regardless of method of assessment, and after alternate courses would be appropriate. The responses claimed and the audited response classification are shown in Table 1 . Fourteen patients had their claimed response confirmed to give a final response rate of 15.2%, although one claimed complete responder was confirmed only as a partial responder ( Table 2) . Ten of these patients had their lesions assessed by CTscan, two by ultrasound and two by both CT and US.
Ten patients (41.7% of those with claimed responses) were rejected as responders by the review panel ( Table  2) . Seven of these patients had their lesions assessed by CTscan, two by ultrasound and one by both procedures. All but two of the patients had lesions which could be remeasured with no difficulty, but four patients had a < 50% reduction in tumour mass and four had progressive disease, resulting in rejection of the claimed response. One was not qualified because either the lesion did not measure at least 2 cm or the lesion could not clearly be delineated from adjacent normal structures.
Ideally, all patients should be reviewed, and certainly all those with stable disease (25 in this study), to ensure that possible partial responses are not being inadvertently overlooked. Many patients were considered to have stable disease on the basis of their clinical status or investigations other than the radiology. Only those patients claimed as responders were reviewed, so the true response rate may be higher than we have reported. However, in clinical trials of new oncolytic agents optimism is high and it is unlikely that many potential responders will be overlooked. A number of additional issues arose out of the independent review. Screening eligibility as regards lesion size was questioned for two patients, although radiologically they were clearly responders and two patients were considered by the reviewer but not by the investigator to have non-measurable, but evaluable disease. The review panel decided that taking all factors into account, including duration of response and clinical status, all of these patients should be included and three of these were responders and one had stable disease. For one patient, an additional indicator lesion was identified although this did not affect confirmation of the response.
Conclusions
Non-comparator, open-label studies are commonly carried out in the development of new oncology treatments as the endpoints are considered to be sufficiently objective and well defined to allow comparison with historical controls. In these circumstances, a reliable, objective assessment of treatment response is of prime importance, as it is in the patient's and clinician's best interests that only active treatments are further developed.
Independent confirmation of treatment response has only recently been introduced to oncology trials. During earlier studies on hexamethylmelamine, ifosfamide and etoposide in ovarian cancer, there was no mention of independent verification of responses [6] [7] [8] [9] [10] [11] . A recent multicentre European-Canadian study of paclitaxel in ovarian cancer, however, employed confirmation of response by an external panel of independent radiologists [17] , in contrast to a 1000 patient NCI treatment referral study of paclitaxel in the United States reviewed selected cases only during the regular three-year audit procedure [18] . These studies did not provide details of the review process and there seems to be a lack of standardised methodology for independent review.
The recent updated Commission on Proprietary Medicinal Products (CPMP) draft guidelines for oncolytics make reference to the need for independent review of responses [19] . There is also recent evidence of the growing use of an independent review process. Studies carried out in the recent years of both docetaxel and gemcitabine, novel chemotherapeutic agents under development in a range of solid tumours, have demonstrated the benefit of such a procedure. Phase II studies of docetaxel in breast cancer [12, 13] and of gemcitabine in breast cancer, pancreatic cancer and non-small-cell lung cancer [14] [15] [16] , describe independent reviews performed by external boards, some of which specifically included a radiologist as part of the team. Indeed, one report describes the assessment procedure and criteria for confirmation of response in some detail [13] . The three gemcitabine trials in non-small-cell lung cancer reviewed independently [16] all had closely similar response rates of 20%-22.5% which can only increase confidence in the reliability of the results reported.
The phase II/III clinical programme for topotecan in ovarian cancer has included an independent review process to obtain as objective and accurate assessment of treatment efficacy as was possible. The results of the review procedure now reported emphasise the importance of this objective in trials where response is the primary endpoint. Of the 24 patients with a claimed response, peer review discussions resulted in 10 patients (41.7%) being rejected as responders on the basis of failing to fulfil all of the strict criteria for response. This was largely due to the difficulty in accurately measuring metastatic disease from ovarian carcinoma, which is known to be a difficult tumour type to image because of peritoneal metastases and tumour invading bowel and the mesentery preventing measurement of lesions at these sites even after rejection of these patients. The response rate for topotecan was 15.2%, similar to the response rate of 15% observed with paclitaxel [17] .
Comparable data are not widely available in the literature. Although the use of external review boards is mentioned, the proportion of claimed responses which were not confirmed is rarely reported. There are, however, a few exceptions. During a large European-Canadian study of paclitaxel in ovarian cancer, 74 patients were initially recorded as responders, but third-party review failed to confirm this response in eight patients (10.8%) [17] . Similarly, three phase II trials of docetaxel in ovarian cancer reported that 31 of the 94 patients (33.0%) originally recorded as responders were later considered non-evaluable due to radiological findings at external review [20] .
It was clear from the review process described that response evaluation using cross-sectional imaging such as CT, as in this trial, (or MRI which was not used in this trial), is the method of choice in the context of a clinical trial. Cross-sectional imaging allows for quantitative re-assessment at a later date, unlike ultrasound which only allows for partial quantitative re-assessment because it is very difficult to interpret the hard copy films of ultrasound examinations performed by others. The ultrasound report is based largely on the impression obtained from the real time image on the screen and not on the hard copy films. By altering the orientation of the ultrasound probe, more subtle features may be apparent and any lesion can be made to appear smaller due to foreshortening. It has to be assumed that the hard copy films sent for review are a true and accurate reflection of events, but the exact angle at which the probe was held is unknown, so it is impossible to determine whether the lesion has been foreshortened and therefore whether the measurements are reliable. Also anatomical landmarks are difficult to visualise. Physical factors such as obesity, ascites and gas in the bowel significantly degrade the image and the latter often prevents the para-aortic region being visualised at all. Air swallowing is common in patients who are in pain, so para-aortic lymphadenopathy often cannot be assessed in such patients. Standardisation of ultrasound protocols are thus virtually impossible, so the use of ultrasound in phase II studies, where reliable measurements are required, should be strongly discouraged. Chest radiographs were allowed for response evaluation in this study, but all claimed responses were assessed by CTor ultrasound, so a direct comparison of the relative sensitivities of CT and chest X-rays cannot be made from these results. Chest radiographs are, however, adequate where lesions are clearly delineated, but lack sensitivity because some areas, such as the paratracheal, subcarinal regions, the hila and those obscured by the cardiac contour and diaphragm, the so-called 'hidden areas', are not adequately demonstrated, unlike CT where these areas are clearly seen. Measurement is only accurate if standardised procedures have been used (e.g. a postero-anterior [P-A] radiograph performed in full inspiration) because of magnification factors. A complete CT scan sequence, however, allows a reviewer to re-assess the whole radiological picture both qualitatively and quantitatively.
Some of the CT scans provided in this study were, however, difficult to remeasure due to the presence of, for example, unopacified loops of bowel which have the same attenuation coefficients as soft tissue and can be misinterpreted as representing peritoneal lesions, or inability to delineate the border of lesions adjacent to blood vessels when an intravenous contrast medium had not been used. This demonstrates the need for a standard protocol to be adopted for oncology trials, where the accurate assessment of 'measurable disease' is of critical importance so that patients in clinical trials can be assessed objectively. This is particularly important during the development of new oncolytic agents where initial optimism is high. In this study, one claimed responder was ineligible for the study because although disease was clearly present and responded to treatment, individual lesions were either not greater than 2 cm diameter or the lesions were not bidimensionally measurable. The use of an intravenous contrast agent would have defined the margins of the aorta and inferior vena cava so the lesion would have been easily measurable. The wide variation in CT scanning protocols demonstrates the difference between clinical practice and phase II studies. In the former, the radiologist is simply asked, 'has the disease progressed, remained constant or responded?' This can be assessed relatively easily and accurately by 'eye-balling' the scans and, although subjective, it is satisfactory for clinical practice.
Response rates are of importance in phase II trials where an objective assessment of activity of a new oncolytic agent is required. The only objective measurements we have at present are response rate, time to progression and survival. Survival is the key issue, and there can be no doubt about this endpoint, but the time taken to establish these data from phase III trials is likely to be several extra years. Response rate is, therefore, used as an interim surrogate for survival. The premise is, if the tumour decreases in size (by an arbitrary figure, usually 50% or more), this will lead to an improvement in clinical condition, quality of life and, hopefully, survival. Unfortunately, response rate does not necessarily correlate with any of these parameters. In patients receiving palliative treatment, the balance between survival, quality of life and effects of treatment versus side effects and no treatment or best supportive care are all important, and this is an attempt to measure one of these parameters objectively. Standard, adequate radiological protocols are important in enabling reproducibility and comparability with future studies using the same agent and allows some comparison with other agents.
A fair comparison of response rates cannot be made with historical controls because advances in imaging techniques have altered our assessment criteria. Comparisons will inevitably be made but should be done so with caution. Currently, the anatomical site and lesion size is all that is being measured. It is less than ideal, but the best interim objective measure we have. The FDA have recognised this, and will be authorising registration for new oncolytic agents in refractory tumour types based on response rates, thereby allowing new active agents to be used in clinical practice at a much earlier stage than currently. It is likely that purely anatomical assessments will be superseded by the addition of functional imaging techniques, such as positron emission spectroscopy and magnetic resonance spectroscopy, so both the anatomy and physiology or pathology can be demonstrated. As yet, these techniques lack sensitivity and resolution, and so we have to use anatomical parameters alone.
The independent radiologist found that re-assessment was aided by the provision of as much additional information as possible even if, apparently, not directly relevant to lesion measurement. This applied not only to retention of the complete CTscan record (missing in one patient in this study), but also to any medical history which would explain abnormalities revealed by the scans, for example if a patient had only one kidney which could be due either to a congenital abnormality or prior nephrectomy which may be relevant. The verification of source documentation is a requirement under GCP, but two reports have shown significant variation between centres in the recording of demographic data, compliance with protocol administration of chemotherapy and treatment-related toxicity [21, 22] . The authors proposed the use of a systematic checklist to standardise data collection which, if implemented, would improve the quality of the data in the CRF and hence more accurate response assessment. This is the first time the imaging modalities and their associated advantages and limitations have been presented in detail with regard to oncological clinical trials. The use of independent review in this study highlighted a number of issues; for instance, all patients with stable disease could have been reviewed to ensure potential responders were not inadvertently overlooked and imaging could have been undertaken after alternate cycles regardless of imaging modality. As a consequence of our experience with this trial, changes have been instituted to new protocols to help further improve objectivity and consistency. The objective assessment of response of tumours to new oncolytic agents in the interim before survival data is available is a difficult area, but radiological imaging can play a significant role even in tumour types which are difficult to image such as ovarian carcinoma. It is likely that independent review will in general terms become standard and a requirement by regulatory authorities and this study represents an effort to improve objectivity and to ultimately standardise and alter older style protocols.
Experience in this clinical trial showed that the use of an independent reviewer in conjunction with peer review ensured that all claimed responses were evaluated according to changes in tumour size with the result that response criteria were rigorously and consistently applied. This resulted in a decrease in response rate from 24 patients out of 93 (25.8%) considered to be eligible to 14/92 (15.2%). It also demonstrates that ovarian carcinoma is a difficult tumour type to visualise and measure but it could partly be overcome by standardising crosssectional imaging protocols and the use of contrast media.
